FDA Action Alert: Argenx, Aldeyra, Intercept and Sarepta

The FDA has four target action dates this week, including ones for Argenx’s subcutaneous efgartigimod in generalized myasthenia gravis and Sarepta’s gene therapy for Duchenne muscular dystrophy.